NYSE:CLB - Core Laboratories Stock Price, Price Target & More

$121.50 -0.30 (-0.25 %)
(As of 04/22/2018 12:26 PM ET)
Previous Close$121.50
Today's Range$120.00 - $122.01
52-Week Range$86.55 - $122.78
Volume403,429 shs
Average Volume393,730 shs
Market Capitalization$5.37 billion
P/E Ratio60.75
Dividend Yield1.81%
Beta1.41

About Core Laboratories (NYSE:CLB)

Core Laboratories logoCore Laboratories N.V. provides reservoir description, and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates in two segments, Reservoir Description and Production Enhancement segments. The Reservoir Description segment comprises the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs. This segment offers laboratory-based analytical and field services to characterize properties of crude oil and petroleum products to the oil and gas industry. It also provides proprietary and joint industry studies. The Production Enhancement segment includes services and products relating to reservoir well completions, perforations, stimulations, and production. This segment offers integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions to improve the effectiveness of enhanced oil recovery projects. The company markets and sells its products through a combination of sales representatives, technical seminars, trade shows, and print advertising, as well as through distributors. Core Laboratories N.V. was founded in 1936 and is based in Amsterdam, the Netherlands.

Receive CLB News and Ratings via Email

Sign-up to receive the latest news and ratings for CLB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Oil & gas field services, not elsewhere classified
Sub-IndustryN/A
SectorOils/Energy
SymbolNYSE:CLB
CUSIPN/A
Phone31-20-420-3191

Debt

Debt-to-Equity Ratio1.53%
Current Ratio1.98%
Quick Ratio1.66%

Price-To-Earnings

Trailing P/E Ratio60.75
Forward P/E Ratio45.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$659.81 million
Price / Sales8.13
Cash Flow$2.5665 per share
Price / Cash47.34
Book Value$3.37 per share
Price / Book36.05

Profitability

EPS (Most Recent Fiscal Year)$2.00
Net Income$83.12 million
Net Margins12.60%
Return on Equity58.25%
Return on Assets15.16%

Miscellaneous

Employees4,600
Outstanding Shares44,160,000

How to Become a New Pot Stock Millionaire

Core Laboratories (NYSE:CLB) Frequently Asked Questions

What is Core Laboratories' stock symbol?

Core Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "CLB."

How often does Core Laboratories pay dividends? What is the dividend yield for Core Laboratories?

Core Laboratories announced a quarterly dividend on Tuesday, April 17th. Stockholders of record on Friday, April 27th will be given a dividend of $0.55 per share on Tuesday, May 22nd. This represents a $2.20 dividend on an annualized basis and a dividend yield of 1.81%. The ex-dividend date is Thursday, April 26th. View Core Laboratories' Dividend History.

How were Core Laboratories' earnings last quarter?

Core Laboratories (NYSE:CLB) issued its earnings results on Wednesday, January, 31st. The oil and gas company reported $0.58 EPS for the quarter, meeting analysts' consensus estimates of $0.58. The oil and gas company had revenue of $172 million for the quarter, compared to analyst estimates of $171.92 million. Core Laboratories had a net margin of 12.60% and a return on equity of 58.25%. The business's quarterly revenue was up 15.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.41 earnings per share. View Core Laboratories' Earnings History.

When is Core Laboratories' next earnings date?

Core Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, April, 25th 2018. View Earnings Estimates for Core Laboratories.

What guidance has Core Laboratories issued on next quarter's earnings?

Core Laboratories issued an update on its first quarter earnings guidance on Wednesday, January, 31st. The company provided EPS guidance of $0.56-0.58 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.61. The company issued revenue guidance of $168-172 million, compared to the consensus revenue estimate of $175.43 million.

What price target have analysts set for CLB?

11 brokerages have issued 12 month price targets for Core Laboratories' shares. Their forecasts range from $96.00 to $136.00. On average, they anticipate Core Laboratories' stock price to reach $111.1940 in the next twelve months. View Analyst Ratings for Core Laboratories.

Who are some of Core Laboratories' key competitors?

Who are Core Laboratories' key executives?

Core Laboratories' management team includes the folowing people:
  • Mr. David M. Demshur, Chairman of Supervisory Board & CEO (Age 63)
  • Mr. Richard L. Bergmark, Chief Financial Officer, Exec. VP and Supervisory Director (Age 65)
  • Mr. Monty L. Davis, Chief Operating Officer and Sr. VP (Age 64)
  • Mr. Lawrence V. Bruno, Pres
  • Mr. Christopher Scott Hill, Sr. VP & Chief Accounting Officer (Age 48)

Has Core Laboratories been receiving favorable news coverage?

Media coverage about CLB stock has trended somewhat negative this week, according to Accern. The research firm rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Core Laboratories earned a media sentiment score of -0.02 on Accern's scale. They also gave media headlines about the oil and gas company an impact score of 46.38 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of Core Laboratories?

Shares of CLB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Core Laboratories' stock price today?

One share of CLB stock can currently be purchased for approximately $121.50.

How big of a company is Core Laboratories?

Core Laboratories has a market capitalization of $5.37 billion and generates $659.81 million in revenue each year. The oil and gas company earns $83.12 million in net income (profit) each year or $2.00 on an earnings per share basis. Core Laboratories employs 4,600 workers across the globe.

How can I contact Core Laboratories?

Core Laboratories' mailing address is STRAWINSKYLAAN 913 TOWER A LEVEL 9, AMSTERDAM P7, 1077 XX. The oil and gas company can be reached via phone at 31-20-420-3191 or via email at [email protected]


MarketBeat Community Rating for Core Laboratories (CLB)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  298 (Vote Outperform)
Underperform Votes:  434 (Vote Underperform)
Total Votes:  732
MarketBeat's community ratings are surveys of what our community members think about Core Laboratories and other stocks. Vote "Outperform" if you believe CLB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLB will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Core Laboratories (NYSE:CLB) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for Core Laboratories in the last 12 months. Their average twelve-month price target is $111.1940, suggesting that the stock has a possible downside of 8.48%. The high price target for CLB is $136.00 and the low price target for CLB is $96.00. There are currently 7 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.362.332.332.29
Ratings Breakdown: 0 Sell Rating(s)
7 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $111.1940$111.3940$110.20$110.9091
Price Target Upside: 8.48% downside3.20% upside5.25% downside26.39% upside

Core Laboratories (NYSE:CLB) Consensus Price Target History

Price Target History for Core Laboratories (NYSE:CLB)

Core Laboratories (NYSE:CLB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2018CowenSet Price TargetHold$98.00LowView Rating Details
3/15/2018Credit Suisse GroupInitiated CoverageOutperform$130.00 -> $107.94MediumView Rating Details
3/13/2018Piper JaffrayInitiated CoverageNeutral -> Neutral$96.00LowView Rating Details
1/30/2018Royal Bank of CanadaSet Price TargetBuy$125.00LowView Rating Details
1/11/2018Deutsche BankDowngradeBuy -> Hold$116.30 -> $109.00MediumView Rating Details
1/9/2018ABN AmroDowngradeBuy -> HoldLowView Rating Details
12/7/2017Loop CapitalSet Price TargetBuy$115.00LowView Rating Details
10/25/2017UBSLower Price TargetNeutral$110.00 -> $100.00N/AView Rating Details
10/25/2017ScotiabankSet Price TargetHold$136.00N/AView Rating Details
8/7/2017Morgan StanleyLower Price TargetOverweight -> Overweight$130.00 -> $125.00MediumView Rating Details
7/26/2017CitigroupLower Price TargetNeutral$102.00 -> $100.00LowView Rating Details
3/23/2017Tudor PickeringInitiated CoverageHoldLowView Rating Details
12/7/2016StephensDowngradeEqual Weight -> Sell$91.00N/AView Rating Details
12/6/2016GuggenheimDowngradeBuy -> NeutralN/AView Rating Details
10/5/2016DA DavidsonInitiated CoverageBuy$136.00N/AView Rating Details
7/12/2016JPMorgan ChaseDowngradeNeutral -> UnderweightN/AView Rating Details
6/13/2016KLR GroupReiterated RatingBuy$166.00 -> $180.00N/AView Rating Details
4/23/2016SimmonsReiterated RatingHold$105.00 -> $115.00N/AView Rating Details
(Data available from 4/22/2016 forward)

Earnings

Core Laboratories (NYSE:CLB) Earnings History and Estimates Chart

Earnings by Quarter for Core Laboratories (NYSE:CLB)

Core Laboratories (NYSE:CLB) Earnings Estimates

2018 EPS Consensus Estimate: $3.44
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.73$0.73$0.73
Q2 20181$0.84$0.84$0.84
Q3 20181$1.00$1.00$1.00
Q4 20182$0.65$1.08$0.87

Core Laboratories (NYSE CLB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/25/2018$0.58N/AView Earnings Details
1/31/2018After Market$0.58$0.58$171.92 million$172.00 millionViewN/AView Earnings Details
10/23/20179/30/2017$0.44$0.48$160.94 million$166.20 millionViewN/AView Earnings Details
7/24/20176/30/2017$0.51$0.52$168.23 million$163.90 millionViewN/AView Earnings Details
4/19/20173/31/2017$0.39$0.42$150.44 million$157.81 millionViewN/AView Earnings Details
1/25/201712/31/2016$0.41$0.41$145.78 million$149.54 millionViewN/AView Earnings Details
10/19/2016Q316$0.38$0.38$155.72 million$143.50 millionViewN/AView Earnings Details
7/20/2016Q216$0.35$0.35$146.37 million$148.10 millionViewN/AView Earnings Details
4/20/2016Q116$0.37$0.37$161.24 million$153.65 millionViewN/AView Earnings Details
1/27/2016Q415$0.65$0.65$179.48 million$182.70 millionViewListenView Earnings Details
10/21/2015Q315$0.83$0.83$203.29 million$197.27 millionViewListenView Earnings Details
7/22/2015Q215$0.77$0.82$195.13 million$204.00 millionViewListenView Earnings Details
4/22/2015Q115$0.85$0.86$211.82 million$213.64 millionViewN/AView Earnings Details
1/28/2015Q414$1.54$1.54$280.18 million$278.60 millionViewN/AView Earnings Details
10/22/2014Q314$1.52$1.53$284.30 million$276.14 millionViewListenView Earnings Details
7/23/2014Q214$1.35$1.35$269.70 million$267.56 millionViewListenView Earnings Details
4/23/2014Q114$1.45$1.45$283.02 million$262.90 millionViewListenView Earnings Details
1/30/2014Q413$1.40$1.43$278.55 million$276.30 millionViewListenView Earnings Details
10/17/2013Q313$1.34$1.36$267.21 million$273.16 millionViewN/AView Earnings Details
7/17/2013Q2 2013$1.31$1.32$267.24 million$263.14 millionViewListenView Earnings Details
4/17/2013Q1 2013$1.15$1.22$260.90 million$260.90 millionViewListenView Earnings Details
1/30/2013Q4 2012$1.13$1.17$246.49 million$254.46 millionViewListenView Earnings Details
10/17/2012$1.10$1.13ViewN/AView Earnings Details
7/18/2012$1.16$1.16ViewN/AView Earnings Details
4/18/2012$1.07$1.06ViewN/AView Earnings Details
2/1/2012$1.08$1.09ViewN/AView Earnings Details
10/19/2011$0.99$0.93ViewN/AView Earnings Details
7/20/2011Q2 2011$0.88$0.90ViewN/AView Earnings Details
4/19/2011$0.75$0.77ViewN/AView Earnings Details
2/9/2011$0.81$0.84ViewN/AView Earnings Details
10/20/2010Q3 2010$0.78$0.80ViewN/AView Earnings Details
7/21/2010Q2 2010$0.72$0.71ViewN/AView Earnings Details
4/28/2010Q1 2010$0.68$0.69ViewN/AView Earnings Details
2/10/2010Q4 2009$0.61$0.62ViewN/AView Earnings Details
10/21/2009Q3 2009$0.57$0.58ViewN/AView Earnings Details
7/22/2009Q2 2009$0.63$0.66ViewN/AView Earnings Details
4/22/2009Q1 2009$0.66$0.63ViewN/AView Earnings Details
2/11/2009Q4 2008$0.83$0.83ViewN/AView Earnings Details
10/22/2008Q3 2008$0.80$0.80ViewN/AView Earnings Details
7/23/2008Q2 2008$0.75$0.76ViewN/AView Earnings Details
4/23/2008Q1 2008$0.68$0.69ViewN/AView Earnings Details
2/13/2008Q4 2007$0.68$0.68ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Core Laboratories (NYSE:CLB) Dividend Information

Core Laboratories pays an annual dividend of $2.20 per share, with a dividend yield of 1.81%. CLB's next quarterly dividend payment will be made on Tuesday, May 22. Core Laboratories pays out 110.00% of its earnings out as a dividend.
Next Dividend:5/22/2018
Annual Dividend:$2.20
Dividend Yield:1.81%
Dividend Growth:3.20% (3 Year Average)
Payout Ratio:110.00% (Trailing 12 Months of Earnings)
81.48% (Based on This Year's Estimates)
67.48% (Based on Next Year's Estimates)
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Core Laboratories (NYSE:CLB)

Core Laboratories (NYSE:CLB) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/17/2018Quarterly$0.551.8%4/26/20184/27/20185/22/2018
1/16/2018Quarterly$0.552.03%1/25/20181/26/20182/16/2018
10/10/2017quarterly$0.5510/19/201710/20/201711/21/2017
7/6/2017Quarterly$0.552.11%7/13/20177/17/20178/14/2017
4/19/2017quarterly$0.551.98%4/27/20174/28/20175/23/2017
1/10/2017Quarterly$0.551.8%1/18/20171/20/20172/17/2017
10/11/2016Quarterly$0.551.95%10/19/201610/21/201611/22/2016
7/7/2016Quarterly$0.557/14/20167/18/20168/15/2016
4/15/2016Quarterly$0.555/2/20165/4/20165/24/2016
1/11/2016Quarterly$0.552.28%1/20/20161/22/20162/19/2016
10/13/2015Quarterly$0.5510/21/201510/23/201511/24/2015
7/7/2015quarterly$0.552.02%7/15/20157/17/20158/17/2015
1/12/2015$0.551/21/20151/23/20152/20/2015
10/6/2014quarterly$0.501.39%10/16/201410/17/201411/25/2014
7/8/2014quarterly$0.507/16/20147/18/20148/18/2014
4/14/2014quarterly$0.501.33%4/23/20144/25/20145/23/2014
1/13/2014quarterly$0.501.05%1/22/20141/24/20142/21/2014
10/8/2013quarterly$0.320.73%10/16/201310/18/201311/20/2013
7/9/2013quarterly$0.320.82%7/17/20137/19/20138/19/2013
4/15/2013quarterly$0.321.01%4/24/20134/26/20135/24/2013
1/11/2013quarterly$0.321/22/20132/22/2013
(Data available from 1/1/2013 forward)

Insider Trades

Core Laboratories (NYSE CLB) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.00%
Insider Trading History for Core Laboratories (NYSE:CLB)
Institutional Ownership by Quarter for Core Laboratories (NYSE:CLB)

Core Laboratories (NYSE CLB) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/1/2017Michael StraughenDirectorBuy106$118.65$12,576.90106View SEC Filing  
1/30/2017Martha Z CarnesDirectorBuy200$115.20$23,040.00200View SEC Filing  
2/2/2016Jan Willem SodderlandDirectorBuy300$93.90$28,170.002,452View SEC Filing  
5/12/2015Michael C KearneyDirectorSell1,000$128.52$128,520.00View SEC Filing  
11/17/2014Mark F ElvigVPSell1,000$138.03$138,030.00View SEC Filing  
7/28/2014Richard L BergmarkCFOBuy7,000$147.31$1,031,170.00View SEC Filing  
3/7/2014Michael KearneyDirectorSell2,000$193.00$386,000.0010,361View SEC Filing  
2/14/2014Mark ElvigVPSell1,500$186.64$279,960.0015,784View SEC Filing  
10/21/2013Monty L DavisCOOSell5,704$197.33$1,125,570.32View SEC Filing  
8/7/2013Richard BergmarkCFOSell20,000$149.58$2,991,600.0038,853View SEC Filing  
7/25/2013Charles Brigham MillerCAOSell11,648$147.81$1,721,690.88View SEC Filing  
7/25/2013Monty L DavisCOOSell5,948$149.12$886,965.76View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Core Laboratories (NYSE CLB) News Headlines

Source:
DateHeadline
Core Laboratories (CLB) Announces Quarterly Dividend of $0.55Core Laboratories (CLB) Announces Quarterly Dividend of $0.55
www.americanbankingnews.com - April 21 at 10:04 AM
Why Did Schlumberger’s 1Q18 Earnings Beat Estimates?Why Did Schlumberger’s 1Q18 Earnings Beat Estimates?
finance.yahoo.com - April 20 at 5:12 PM
Core Laboratories (CLB) Downgraded by Zacks Investment Research to HoldCore Laboratories (CLB) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - April 18 at 12:50 PM
Core Laboratories (CLB) Scheduled to Post Earnings on WednesdayCore Laboratories (CLB) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - April 18 at 5:03 AM
Core Laboratories (CLB) Downgraded to Strong Sell at Zacks Investment ResearchCore Laboratories (CLB) Downgraded to Strong Sell at Zacks Investment Research
www.americanbankingnews.com - April 17 at 10:55 PM
The Man Behind the President’s TweetsThe Man Behind the President’s Tweets
www.nytimes.com - April 17 at 5:45 PM
Core Lab Announces Q2 2018 Quarterly DividendCore Lab Announces Q2 2018 Quarterly Dividend
finance.yahoo.com - April 17 at 5:45 PM
Core Laboratories (CLB) Lifted to "Buy" at Zacks Investment ResearchCore Laboratories (CLB) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 17 at 12:47 PM
Baker Hughes, a GE Company: Will 1Q18 Earnings Decline?Baker Hughes, a GE Company: Will 1Q18 Earnings Decline?
finance.yahoo.com - April 16 at 5:11 PM
Piper Jaffray Analysts Give Core Laboratories (CLB) a $97.00 Price TargetPiper Jaffray Analysts Give Core Laboratories (CLB) a $97.00 Price Target
www.americanbankingnews.com - April 15 at 11:42 PM
Core Laboratories (CLB) Rating Lowered to Sell at BidaskClubCore Laboratories (CLB) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 15 at 12:04 AM
Is Core Laboratories NV a Buy?Is Core Laboratories NV a Buy?
www.fool.com - April 13 at 5:20 PM
Core Laboratories (CLB) Given a $98.00 Price Target by Cowen AnalystsCore Laboratories (CLB) Given a $98.00 Price Target by Cowen Analysts
www.americanbankingnews.com - April 13 at 12:25 PM
Core Laboratories (CLB) Expected to Announce Quarterly Sales of $171.06 MillionCore Laboratories (CLB) Expected to Announce Quarterly Sales of $171.06 Million
www.americanbankingnews.com - April 13 at 4:06 AM
Is Core Laboratories N.V. a Buy?Is Core Laboratories N.V. a Buy?
www.msn.com - April 12 at 8:57 AM
Core Laboratories (CLB) Raised to "Hold" at ValuEngineCore Laboratories (CLB) Raised to "Hold" at ValuEngine
www.americanbankingnews.com - April 11 at 12:37 PM
Core Laboratories (CLB) Expected to Post Earnings of $0.58 Per ShareCore Laboratories (CLB) Expected to Post Earnings of $0.58 Per Share
www.americanbankingnews.com - April 11 at 7:10 AM
BidaskClub Lowers Core Laboratories (CLB) to Strong SellBidaskClub Lowers Core Laboratories (CLB) to Strong Sell
www.americanbankingnews.com - April 10 at 3:55 PM
Core Laboratories (CLB) Set to Announce Quarterly Earnings on TuesdayCore Laboratories (CLB) Set to Announce Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 10 at 1:29 AM
Core Laboratories (CLB) Lowered to "Hold" at Zacks Investment ResearchCore Laboratories (CLB) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 9 at 1:57 PM
Core Laboratories (CLB) Research Coverage Started at Deutsche BankCore Laboratories (CLB) Research Coverage Started at Deutsche Bank
www.americanbankingnews.com - April 7 at 6:36 PM
Core Laboratories (CLB) Stock Rating Lowered by Zacks Investment ResearchCore Laboratories (CLB) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 6 at 8:47 PM
Core Laboratories (CLB) PT Set at $136.00 by ScotiabankCore Laboratories (CLB) PT Set at $136.00 by Scotiabank
www.americanbankingnews.com - April 5 at 4:38 PM
Core Laboratories (CLB) Given New $115.00 Price Target at Loop CapitalCore Laboratories (CLB) Given New $115.00 Price Target at Loop Capital
www.americanbankingnews.com - April 5 at 4:06 PM
Core Laboratories (CLB) Upgraded by ABN Amro to BuyCore Laboratories (CLB) Upgraded by ABN Amro to Buy
www.americanbankingnews.com - April 5 at 2:58 PM
Core Laboratories (CLB) Given New $100.00 Price Target at UBSCore Laboratories (CLB) Given New $100.00 Price Target at UBS
www.americanbankingnews.com - April 5 at 2:27 PM
Core Laboratories First Quarter 2018 Webcast At 7:30 A.M. CDT / 2:30 P.M. CEST On April 26, 2018Core Laboratories' First Quarter 2018 Webcast At 7:30 A.M. CDT / 2:30 P.M. CEST On April 26, 2018
www.prnewswire.com - April 4 at 4:16 PM
Core Laboratories (CLB) Upgraded to "Buy" by Zacks Investment ResearchCore Laboratories (CLB) Upgraded to "Buy" by Zacks Investment Research
www.americanbankingnews.com - April 4 at 12:45 PM
Important JAMA Article Underscores Superiority of Precipios Liquid Biopsy Core TechnologyImportant JAMA Article Underscores Superiority of Precipio's Liquid Biopsy Core Technology
globenewswire.com - April 3 at 5:22 PM
Core Laboratories (CLB) Rating Increased to Hold at Zacks Investment ResearchCore Laboratories (CLB) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - April 2 at 12:26 PM
Core Laboratories (CLB) Lowered to Hold at ABN AmroCore Laboratories (CLB) Lowered to Hold at ABN Amro
www.americanbankingnews.com - March 30 at 12:22 AM
Core Laboratories (CLB) Given Average Rating of "Hold" by AnalystsCore Laboratories (CLB) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - March 29 at 3:24 AM
Core Laboratories (CLB) Rating Lowered to Hold at Deutsche BankCore Laboratories (CLB) Rating Lowered to Hold at Deutsche Bank
www.americanbankingnews.com - March 28 at 10:55 PM
Analysts’ Targets for Top Free-Cash-Generating OFS StocksAnalysts’ Targets for Top Free-Cash-Generating OFS Stocks
finance.yahoo.com - March 27 at 5:04 PM
The Top 5 Oilfield Companies by Free Cash FlowThe Top 5 Oilfield Companies by Free Cash Flow
finance.yahoo.com - March 26 at 5:07 PM
Core Laboratories (CLB) Given a $125.00 Price Target by Royal Bank of Canada AnalystsCore Laboratories (CLB) Given a $125.00 Price Target by Royal Bank of Canada Analysts
www.americanbankingnews.com - March 26 at 1:26 PM
Core Laboratories (CLB) Stock Rating Upgraded by TheStreetCore Laboratories (CLB) Stock Rating Upgraded by TheStreet
www.americanbankingnews.com - March 25 at 11:29 AM
Head-To-Head Analysis: Core Laboratories (CLB) and Dril-Quip (DRQ)Head-To-Head Analysis: Core Laboratories (CLB) and Dril-Quip (DRQ)
www.americanbankingnews.com - March 23 at 3:06 AM
Core Laboratories (CLB) Research Coverage Started at Piper Jaffray CompaniesCore Laboratories (CLB) Research Coverage Started at Piper Jaffray Companies
www.americanbankingnews.com - March 18 at 1:00 PM
Core Laboratories (CLB) Coverage Initiated at Credit Suisse GroupCore Laboratories (CLB) Coverage Initiated at Credit Suisse Group
www.americanbankingnews.com - March 15 at 5:28 PM
$171.06 Million in Sales Expected for Core Laboratories (CLB) This Quarter$171.06 Million in Sales Expected for Core Laboratories (CLB) This Quarter
www.americanbankingnews.com - March 10 at 9:24 AM
Core Laboratories (CLB) Upgraded by Zacks Investment Research to "Hold"Core Laboratories (CLB) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - March 6 at 5:16 PM
The Manufacturers Life Insurance Company  Buys 7,995 Shares of Core Laboratories (CLB)The Manufacturers Life Insurance Company Buys 7,995 Shares of Core Laboratories (CLB)
www.americanbankingnews.com - March 6 at 3:13 PM
Core Laboratories (CLB) Downgraded by ValuEngine to SellCore Laboratories (CLB) Downgraded by ValuEngine to Sell
www.americanbankingnews.com - March 4 at 9:28 PM
Lazard Asset Management LLC Raises Stake in Core Laboratories (CLB)Lazard Asset Management LLC Raises Stake in Core Laboratories (CLB)
www.americanbankingnews.com - March 4 at 1:34 PM
Core Laboratories (CLB) Given Average Recommendation of "Hold" by AnalystsCore Laboratories (CLB) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - March 4 at 3:30 AM
Core Laboratories (CLB) Stake Raised by Arizona State Retirement SystemCore Laboratories (CLB) Stake Raised by Arizona State Retirement System
www.americanbankingnews.com - March 3 at 4:22 AM
Core Laboratories (CLB) Position Lifted by Snyder Capital Management L PCore Laboratories (CLB) Position Lifted by Snyder Capital Management L P
www.americanbankingnews.com - March 2 at 1:57 PM
First Republic Investment Management Inc. Reduces Stake in Core Laboratories (CLB)First Republic Investment Management Inc. Reduces Stake in Core Laboratories (CLB)
www.americanbankingnews.com - March 2 at 11:48 AM
Carillon Tower Advisers Inc. Invests $3.33 Million in Core Laboratories (CLB) StockCarillon Tower Advisers Inc. Invests $3.33 Million in Core Laboratories (CLB) Stock
www.americanbankingnews.com - March 2 at 5:34 AM

SEC Filings

Core Laboratories (NYSE:CLB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Core Laboratories (NYSE:CLB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Core Laboratories (NYSE CLB) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.